Clinical trial
A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)
NCT02664558 is registered in ClinicalTrials.gov with Eiger BioPharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)
- Lead sponsor
- Eiger BioPharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2016
- Completion date
- January 31, 2018
- Enrollment
- 61 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.